Report / Paper metadata
Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications.
A later analysis of the JUMP trial described patients with myelofibrosis who received medicines to support anaemia while taking ruxolitinib. Because the comparison groups were not matched or randomly assigned to this additional care, the analysis cannot establish its causal benefit.
Which patients were analysed?
The analysis selected 101 patients with baseline haemoglobin below 12 g/dL who began an erythropoiesis-stimulating agent or danazol within three months of enrolment and continued it for at least three months. Most received an erythropoiesis-stimulating agent. A comparison group contained 1,242 patients with the same baseline haemoglobin threshold who did not begin these medicines within that window.
What responses were reported?
At twenty-four weeks, 37% of the selected group met the study's spleen-length response threshold and 26% met its symptom-response threshold. The corresponding comparison-group rates were 28% and 26%. These are defined trial responses, not cure rates or evidence that the additional medicines improve survival.
Why does the analysis design matter?
This was a post hoc analysis of an existing trial, with an unmatched comparison group. The decision to add anaemia-supporting treatment was not the randomised comparison being evaluated. Other differences between patients or their care could therefore contribute to the observed outcomes. Selecting people who maintained the treatment for at least three months also shapes who appears in the analysis.
What conclusion is supported?
The results describe a group able to continue ruxolitinib with anaemia-supporting care and report responses alongside the broader study population. They do not prove that adding these medicines caused better outcomes or define the best approach for an individual. This abstract-based explanation does not replace prescribing information, a full safety assessment or specialist care.
- Journal
- Hematology (Amsterdam, Netherlands)
- Kind
- Paper metadata
- Identifier
- PMID 42698151